Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Colon Cancer cell line YB5 untreated cells vs YB5 treated 24h with Depsipeptide at 20 nM

ABSTRACT: Study the effect of HDACi Depsipeptide on gene expression. We combined these data with whole genome DNA methylation microarray to test the reactivation of genes that have an hypermethylated promoter region.

ORGANISM(S): Homo sapiens

PROVIDER: GSE34077 | GEO | 2012/04/04

SECONDARY ACCESSION(S): PRJNA156507

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Colon Cancer cell line YB5 untreated cells vs YB5 treated 24h with Depsipeptide at 20 nM

Project description:Study the effect of HDACi Depsipeptide on gene expression. We combined these data with whole genome DNA methylation microarray to test the reactivation of genes that have an hypermethylated promoter region. We did two independant experiments with 2 untreated and 2 treated different batch of cells

2012-04-03 | E-GEOD-34077 | biostudies-arrayexpress

DNA methylation analysis of Colon Cancer cell line SW48

Project description:We combined gene expression experiments in response to HDAC inhibitor Depsipeptide with DNA methylation level to assess gene reactivation arising from hypermethylated promoters.

2012-04-04 | GSE34427 | GEO

DNA methylation analysis of Colon Cancer cell line SW48

2012-04-03 | E-GEOD-34427 | biostudies-arrayexpress

RNA-seq of YB5 cells treated with epigenetic therapy

Project description:RNA-seq was performed after YB5 cells were treated with S2101, UNC0638, GSK343, depsipeptide alone or in combination with decitabine

2016-12-31 | GSE73966 | GEO

ChIP-seq of histone methylation marks in YB5 cells

Project description:ChIP-seq of H3K4me2, H3K9me2, and H3K27me3 was performed in YB5 cells to determine the impact of baseline histone methylation patterns on gene reactivation by epigenetic therapy

2017-01-31 | GSE74269 | GEO

Expression and DNA methylation of colon cancer cell lines

Project description:This SuperSeries is composed of the following subset Series: GSE34077: Colon Cancer cell line YB5 untreated cells vs YB5 treated 24h with Depsipeptide at 20 nM GSE34427: DNA methylation analysis of Colon Cancer cell line SW48 Refer to individual Series

2012-04-03 | E-GEOD-34429 | biostudies-arrayexpress

Real-time fluorescence imaging with 20?nm axial resolution.

Project description: Not available

| S-EPMC4595625 | biostudies-literature

Bright sub-20-nm cathodoluminescent nanoprobes for electron microscopy.

Project description: Not available

| S-EPMC6786485 | biostudies-literature

Venous puncture wound thrombi, 1, 5, 20 min post-puncture, 100 nm XY raw images, 20 nm XY pixels every 20 micons, 3 nm wide area TEM montages at selected depth

Project description: Not available

| EMPIAR-10785 | biostudies-other

Epigenetic therapy for Friedreich ataxia.

Project description:We set out to investigate whether a histone deacetylase inhibitor (HDACi) would be effective in an in vitro model for the neurodegenerative disease Friedreich ataxia (FRDA) and to evaluate safety and surrogate markers of efficacy in a phase I clinical trial in patients. In the neuronal cell model, HDACi 109/RG2833 increases FXN mRNA levels and frataxin protein, with concomitant changes in the epigenetic state of the gene. Chromatin signatures indicate that histone H3 lysine 9 is a key residue for gene silencing through methylation and reactivation through acetylation, mediated by the HDACi. Drug treatment in FRDA patients demonstrated increased FXN mRNA and H3 lysine 9 acetylation in peripheral blood mononuclear cells. No safety issues were encountered. We used a human FRDA neuronal cell model, derived from patient induced pluripotent stem cells, to determine the efficacy of a 2-aminobenzamide HDACi (109) as a modulator of FXN gene expression and chromatin histone modifications. FRDA patients were dosed in 4 cohorts, ranging from 30mg/day to 240mg/day of the formulated drug product of HDACi 109, RG2833. Patients were monitored for adverse effects as well as for increases in FXN mRNA, frataxin protein, and chromatin modification in blood cells. Gene expression profiles were obtained using the Illumina HT12v4 Gene Expression BeadArray.

2015-01-29 | E-GEOD-65399 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data